Cerevel Therapeutics Holdings Alpha and Beta Analysis
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cerevel Therapeutics Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cerevel Therapeutics over a specified time horizon. Remember, high Cerevel Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cerevel Therapeutics' market risk premium analysis include:
Beta (0.19) | Alpha 0.0973 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cerevel |
Cerevel Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cerevel Therapeutics market risk premium is the additional return an investor will receive from holding Cerevel Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cerevel Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cerevel Therapeutics' performance over market.| α | 0.1 | β | -0.19 |
Cerevel Therapeutics Fundamentals Vs Peers
Comparing Cerevel Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cerevel Therapeutics' direct or indirect competition across all of the common fundamentals between Cerevel Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cerevel Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cerevel Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cerevel Therapeutics to competition |
| Fundamentals | Cerevel Therapeutics | Peer Average |
| Return On Equity | -0.92 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Current Valuation | 7.71 B | 16.62 B |
| Shares Outstanding | 182.2 M | 571.82 M |
| Shares Owned By Insiders | 15.32 % | 10.09 % |
| Shares Owned By Institutions | 85.12 % | 39.21 % |
| Number Of Shares Shorted | 5.98 M | 4.71 M |
Cerevel Therapeutics Opportunities
Cerevel Therapeutics Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Calling All Cerevel Therapeutics Holdings, Inc. Investors Contact Bronstein, Gewirtz Grossman, LLC To Claim Your Losses | 05/29/2024 |
2 | AbbVie Stock Price Forecast 200 On The Cards | 06/20/2024 |
3 | Why Is Cerevel Therapeutics Holdings, Inc. One of the Best Healthcare Stocks to Buy Under 50 | 06/27/2024 |
4 | 10 clinical trials to watch in the second half of 2024 | 07/01/2024 |
5 | Entropy Technologies LP Buys Shares of 16,131 Cerevel Therapeutics Holdings, Inc. - MarketBeat | 07/18/2024 |
6 | Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie - Seeking Alpha | 07/22/2024 |
7 | Cerevel stock ticks higher as AbbVie says it expects deal to close soon | 07/25/2024 |
8 | Oil tanker in collision near Pedra Branca did not flee, but had drifted away Malaysian authorities | 07/30/2024 |
9 | Disposition of 81065 shares by Burgess Paul D. of Cerevel Therapeutics subject to Rule 16b-3 | 08/01/2024 |
About Cerevel Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cerevel or other delisted stocks. Alpha measures the amount that position in Cerevel Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Cerevel Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cerevel Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cerevel Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cerevel Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cerevel Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cerevel Therapeutics' management manipulating its earnings.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cerevel Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |